The present invention relates to peptides capable of forming a gel and to their use in tissue engineering and bioprinting. The present invention furthermore relates to a gel comprising a peptide in accordance with the present invention, to a method of preparing such gel and to the use of such gel. In one embodiment, such gel is a hydrogel. The present invention furthermore relates to a wound dressing or wound healing agent comprising a gel according to the present invention and to a surgical implant or stent comprising a peptide scaffold formed by a gel according to the present invention. Moreover, the present invention also relates to a pharmaceutical and/or cosmetic composition, to a biomedical device or an electronic device comprising the peptide according to the present invention.

Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.

The present disclosure provides synthetic collagen and methods of making and using synthetic collagen that include a synthetic collagen that facilitates wound closure comprising an isolated and purified triple helical backbone protein that facilitates wound closure comprising one or more alteration in a triple helical backbone protein sequence, that stabilize the isolated and purified triple helical backbone protein and does not disrupt an additional collagen ligand interaction; and one or more integrin binding motifs, wherein the isolated and purified triple helical backbone protein facilitates wound closure.

The present invention provides a method of producing a modified collagen, including the steps of: providing a collagen comprising a S—S bond; introducing a —SH group in said collagen comprising a S—S bond by reduction of the S—S bond to provide a collagen thiol comprising a —SH group; and nitrosating the —SH group of the collagen thiol to provide a modified collagen, said modified collagen comprising S-nitroso groups.

Hydrogels are provided that include an antimicrobial agent and a cross-linkable urethane-based polymer (CUP). Such hydrogels may be used for the controlled-release of antimicrobial agents as well as in the manufacturing of wound dressings. Wound dressings are provided that comprise a hydrogel as defined herein.

The present invention relates to compounds of Formula I which form hydrogels upon mixing with water, and to fibers which form from the compounds. The hydrogels and fibers are antibacterial and not toxic towards mammalian cells. Such compounds, hydrogels, and fibers are useful, for example, in the treatment of surfaces such as in dermal or internal wounds as a barrier layer, or any article which may require disinfection. (I)

##STR00001##

Liquid dressing compositions liquid for use in the treatment or prevention of infection and/or wounds are described that comprise shellac, an anti-infective metal active and a solvent. The compositions are capable of forming a barrier when topically applied to a subject, providing an easily applied barrier for protecting lesions and other wounds from external infective agents.

The present invention discloses either or both in situ and a priori generated hydrogel wound dressings comprise one or more RTR components in low viscosity aqueous solution and one or more non-RTR components. A dressing, comprising at least one first RTR and an active component (AC) integrated within the RTR is also disclosed. The invention further discloses a method of treating a medical or cosmetic indication by a wound dressing, comprising either or both in situ and a priori generating hydrogel wound dressings by providing one or more RTR components in low viscosity aqueous solution and one or more non-RTR components. it and methods for treating a medical or cosmetic indication by providing a dressing with at least one first RTR and with at least one active component (AC) integrated within the RTR are also disclosed.

The present invention provides a medical dressing article and a method of manufacturing the same, which comprises: (a) a first layer comprised of polycaprocaptone fibers having a PCL fiber diameter of 0.5 μm and 2.9 μm; (b) a second layer, deposited directly on the first layer, including a mixture of polycaprolactone and poloxamer fibers (PCL and POX fibers) wherein a PCL and POX fiber diameter is between 0.1 μm and 4 μm; and (c) a third layer, deposited directly on the second layer, further comprising a mixture of gelatin and silver nitrate (AgNO.sub.3).

Disclosed embodiments relate to a wound dressing which can generate nitric oxide. The wound dressing may include a cover layer, an activator layer such as an acid providing layer and nitric oxide source layer, such as a nitrite providing layer. The activator layer may include acidic groups and may be hydrogel, xerogel, or other suitable material. The nitric oxide source layer may include a nitrite salt. Nitrite ions of the nitric oxide source layer may react with the acidic groups of the activating layer to generate nitric oxide. The activating layer may include a window at the center, and a central absorbent material may be positioned at the window. Various separating layers may also be incorporated into the dressing to control the interaction between activating layer and nitric oxide source layer.